Search Results
Your search for The matches 34659 pages
Showing 3851 - 3900E. John Wherry, PhD, Recognized With the 2023 AACR–Cancer Research Institute Lloyd J. Old Award in Cancer Immunology
The American Association for Cancer Research (AACR) awarded E. John Wherry, PhD, with the 2023 AACR–Cancer Research Institute Lloyd J. Old Award in Cancer Immunology during the AACR Annual Meeting in April in Orlando, Florida. Dr. Wherry is Chair of the Department of Systems Pharmacology and...
Retifanlimab-dlwr for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma
On March 22, 2023, the anti–PD-1 antibody retifanlimab-dlwr was granted accelerated approval for adults with metastatic or recurrent locally advanced Merkel cell carcinoma.1 Supporting Efficacy Data Approval was based on findings in POD1UM-201 (ClinicalTrials.gov identifier NCT03599713), a...
Omidubicel-onlv to Reduce Time to Neutrophil Recovery and Incidence of Infection in Hematologic Malignancies
On April 17, 2023, omidubicel-onlv was approved for use in adult and pediatric patients (≥ 12 years) with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.1 ...
Expert Point of View: Carol Aghajanian, MD
Carol Aghajanian, MD, Chief of the Gynecologic Medical Oncology Service at Memorial Sloan Kettering Cancer Center, New York, commented on the final analysis of NOVA for The ASCO Post. She highlighted the difficulty in truly measuring overall survival in recurrent ovarian cancer. Dr. Aghajanian also ...
NOVA: Final Analysis Confirms No Significant Overall Survival Benefit for Maintenance Niraparib in Recurrent Ovarian Cancer
After resolving missing survival data in the phase III ENGOT-OV16/NOVA trial, no statistically significant difference in overall survival was found for patients with platinum-sensitive recurrent ovarian cancer who received maintenance therapy with the PARP inhibitor niraparib, investigators...
SGO Presentations Explore Inequitable Access to Clinical Trials and Its Impact on Survival
Two studies presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer underscore the importance of enrolling patients with gynecologic cancer on clinical trials and of assuring trial access to racial minorities. One study found a statistically significant...
Expert Point of View: Joshua G. Cohen, MD
Joshua G. Cohen, MD, Associate Clinical Professor in the Department of Surgery and Medical Director of the Orange County Gynecologic Cancer Program at City of Hope, Orange County, California, shared his thoughts on the ADAGIO trial with The ASCO Post. He noted that uterine serous carcinoma—the...
Poor Tolerability Appears to Hinder Benefit of Adavosertib in Uterine Serous Carcinoma
The oral, small-molecule Wee1 kinase inhibitor adavosertib was clinically active but not well tolerated by more than half the patients with recurrent or persistent uterine serous carcinoma in the phase IIb ADAGIO trial. The findings were reported at the Society of Gynecologic Oncology (SGO) 2023...
Expert Point of View: Amanda Nickles Fader, MD
Amanda Nickles Fader, MD, Professor of Gynecology and Obstetrics, Professor of Oncology, and Vice Chair of Gynecologic Surgical Operations at Johns Hopkins Health System, Baltimore, provided her thoughts on GOG 3026 for The ASCO Post. Dr. Fader applauded the investigators and the Gynecologic...
GOG 3026: Durable Responses With Ribociclib Plus Letrozole in Low-Grade Serous Ovarian Cancer
In patients with recurrent low-grade serous ovarian cancer, treatment with ribociclib plus letrozole was not only active, but led to outcomes that are comparable to those achieved with current agents—with a particularly striking 19-month duration of response—according to Brian M. Slomovitz, MD,...
Expert Point of View: Kathleen Moore, MD, MS
Kathleen Moore, MD, MS, the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, spoke with The ASCO Post about GOG-258. According to Dr. Moore, the final results of this long-running...
GOG 258 Final Results: No Improvement in Survival by Adding Radiotherapy to Chemotherapy in Advanced Endometrial Cancer
The long-running randomized NRG Oncology GOG-258 clinical trial failed to identify an overall survival benefit with adjuvant chemoradiotherapy vs chemotherapy alone in any subgroup of patients with locally advanced endometrial cancer. After a median follow-up of 112 months, the hazard ratio for...
Genetic Sequencing May Identify Cancers Often Missed by Traditional Screening Guidelines
Whole-exome sequencing of a large database identified carriers of mutations associated with hereditary cancer syndromes (ie, hereditary breast and ovarian cancers and Lynch syndrome). What was surprising was that among those carriers, about 40% did not satisfy the existing National Comprehensive...
FDA Approves Avapritinib for Indolent Systemic Mastocytosis
On May 22, the U.S. Food and Drug Administration (FDA) approved the tyrosine kinase inhibitor avapritinib (Ayvakit) for the treatment of adults with indolent systemic mastocytosis. Avapritinib is the first and only approved therapy for indolent systemic mastocytosis. Systemic mastocytosis is a rare ...
Expert Point of View: Stephen Lam Chan, MD
Invited discussant of the IMbrave050 trial, Stephen Lam Chan, MD, of Chinese University of Hong Kong, put the study into context. “After curative treatment, recurrence remains a big problem [in patients with hepatocellular carcinoma at high risk of disease recurrence following resection or...
IMbrave050 Trial: Adjuvant Regimen of Atezolizumab Plus Bevacizumab in Resectable Hepatocellular Carcinoma
Adjuvant treatment with the combination of atezolizumab and bevacizumab achieved a statistically significant and clinically meaningful improvement in recurrence-free survival compared with active surveillance alone in patients with high-risk hepatocellular carcinoma following curative-intent...
Expert Point of View: Kenneth C. Anderson, MD
Kenneth C. Anderson, MD, Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute, and Kraft Family Professor of Medicine, Harvard Medical School, was upbeat about the REGN5459 study and the field of melanoma studies in...
Israeli Surgical Oncology Leader Dov Zippel, MD, Considers the Evolving Landscape of Cancer Care in a Small Nation
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Dov Zippel, MD, a surgical oncologist at Sheba Medical Center in Tel Hashomer, Israel, where he is Head of the Meirav Breast Center. Dr. Zippel is the current President of ...
Tumor Mutational Burden and Outcomes in Patients With Advanced Cancers Treated With Immune Checkpoint Inhibitors
In a study reported in JAMA Network Open, Charu Aggarwal, MD, MPH, and colleagues found that patients with advanced solid cancers and a high tumor mutational burden (TMB-H) had improved overall survival with immune checkpoint inhibitor therapy vs those with a low tumor mutational burden (TMB-L)....
Novel Bispecific Antibody for Multiple Myeloma Shows High Response Rates in Early Trial
The bispecific antibody REGN5459 achieved a 90.5% overall response rate when given at the two highest doses in patients with relapsed or refractory multiple myeloma, according to the results of a phase I/II clinical trial.1 Although preliminary, the results of this first-in-human trial for the...
BCG Vaccines May Provide Protective Effect Against Alzheimer's Disease
Researchers have found that patients treated with the Bacillus Calmette-Guérin (BCG) vaccine may have a reduced risk of Alzheimer’s disease and related dementias, according to a novel study published by Weinberg et al in JAMA Network Open. Background The BCG vaccine has been known to offer multiple ...
Addition of Panitumumab to Trifluridine/Tipiracil in Anti-EGFR Treatment Rechallenge in Refractory RAS Wild-Type Metastatic Colorectal Cancer
In the Italian phase II VELO trial reported in JAMA Oncology, Napolitano et al found that anti-EGFR treatment rechallenge with the addition of panitumumab to trifluridine/tipiracil improved progression-free survival in the third-line setting for patients with RAS wild-type metastatic colorectal...
Radical Cystectomy vs Trimodality Therapy for Muscle-Invasive Bladder Cancer
In a retrospective analysis reported in The Lancet Oncology, Zlotta et al found that trimodality therapy was associated with similar outcomes compared to radical cystectomy in patients with muscle-invasive bladder cancer. Study Details The study involved 722 patients with clinical stage T2–T4N0M0...
Partnering With Patients: The Cornerstone of Cancer Care and Research
The health and well-being of our clinicians, our communities, and our care systems need vigilance now more than ever to ensure we keep pace with the effects of change that is also advancing our medicine. When clinicians or patients talk about health care, they might mention frustrations with forms ...
Organizations Team Up to Improve Cancer Care in Rural Appalachia
The Appalachian Community Cancer Alliance (ACCA) has launched a lung cancer screening initiative to improve cancer care in rural Appalachia. Home to nearly 26 million people, the Appalachian region includes all of West Virginia and parts of 12 other states, and it has a 10% higher cancer mortality...
Assay Prediction of pCR in Patients With HER2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab
In an analysis reported in JAMA Oncology, Waks et al found that the HER2DX assay performed well in predicting the likelihood of pathologic complete response (pCR) in patients with early HER2-positive breast cancer receiving de-escalated neoadjuvant treatment with paclitaxel, trastuzumab, and...
Multisystem Inflammatory Syndrome in Children With Cancer and COVID-19
In a U.S. cohort study reported in JAMA Oncology, Martin et al described the clinical course and potential factors associated with post–COVID-19 multisystem inflammatory syndrome in children with cancer also infected with COVID-19. Post–COVID-19 multisystem inflammatory syndrome is a...
Study Analyzes Relationship Between Cancer Survivors’ Tobacco Use, Symptom Burden, and Motivation to Quit Smoking
Investigators have found that current smoking and vaping may be associated with a higher burden of symptoms among adult cancer survivors but that these symptoms may not have had an impact on the desire to quit smoking. The new study was published by Price et al in Cancer. Background Continued...
Late Major Surgical Intervention in Survivors of Childhood Cancer
In an analysis from the Childhood Cancer Survivor Study (CCSS) reported in The Lancet Oncology, Dieffenbach et al found that childhood cancer survivors had a heavy cumulative burden of late major surgical interventions. Study Details The study involved data from the CCSS on 5-year survivors of...
FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory B-Cell Lymphoma
On May 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the bispecific CD20-directed CD3 T-cell engager epcoritamab-bysp (Epkinly) for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)–not otherwise specified, including DLBCL arising from...
Expert Point of View: Sarah Blair, MD
Sarah Blair, MD, Professor and Vice Chair of the Department of Surgery at UC San Diego Health in California, offered her thoughts on the findings from these two studies. She first pointed to the growing body of data showing how nutrition and exercise programs can improve aerobic fitness, quality of ...
Exercise, Wellness Interventions in Early Breast Cancer Demonstrate Measurable Benefits—Even Economic Ones
Specialized exercise and wellness programs significantly elevated physical well-being and quality of life among patients with breast cancer while reducing the use of health-care resources in new research presented at the 2023 American Society of Breast Surgeons Annual Meeting. In one multicenter...
Specialist Palliative Care for Patients Undergoing Major Abdominal Surgery for Cancer
In a single-center trial reported in JAMA Surgery, Shinall et al found that specialist palliative care did not improve quality of life or survival vs usual care in patients undergoing nonpalliative major abdominal surgery for cancer. Study Details In the trial, 235 patients scheduled for specified...
Association Between Overweight/Obesity and Risk of Gastrointestinal Cancer
Researchers have found that individuals in early and middle adulthood who have a body mass index (BMI) indicating that they have overweight or obesity may be at an increased risk of developing gastrointestinal cancer, according to a new study published by Loomans-Kropp and Umar in JAMA Network...
Augmented Early Intensification and Higher Consolidation Methotrexate Dosing Show No Benefit in Childhood ALL
Results of the Intercontinental-Berlin-Frankfurt-Münster 2009 trial in childhood acute lymphoblastic leukemia (ALL) were reported in the Journal of Clinical Oncology by Campbell et al. Findings included no benefit of augmented early intensification in intermediate-risk or high-risk patients and no...
Use of 5α-Reductase Inhibitors and Prostate Cancer Mortality
In a systematic review and meta-analysis reported in JAMA Oncology, Baboudjian et al found no significant association between the use of 5α-reductase inhibitors (5-ARIs) and the risk of prostate cancer mortality. As stated by the investigators, “Recently, several large, high-quality analyses have...
First-Line Venetoclax Combinations vs Chemoimmunotherapy in Fit Patients With CLL
In the phase III GAIA–CLL13 trial reported in The New England Journal of Medicine, Barbara Eichhorst, MD, and colleagues found better outcomes with venetoclax plus obinutuzumab and venetoclax, obinutuzumab, and ibrutinib compared with chemoimmunotherapy as first-line treatment in fit patients with ...
Trastuzumab/Pertuzumab Plus Neoadjuvant Paclitaxel or Endocrine Therapy in Hormone Receptor–Positive, HER2-Positive Early Breast Cancer
In a German phase II trial (WSG-TP-II) reported in JAMA Oncology, Gluz et al found that the addition of neoadjuvant paclitaxel monotherapy to trastuzumab/pertuzumab resulted in a higher pathologic complete response (pCR) rate in patients with hormone receptor–positive, HER2-positive early breast...
Implantable Ultrasound Device to Open Blood-Brain Barrier for Peritumoral Delivery of Albumin-Bound Paclitaxel in Recurrent Glioblastoma
In a small single-institution phase I trial reported in The Lancet Oncology, Sonabend et al found that an implantable device for low-intensity pulsed ultrasound with concomitant administration of intravenous microbubbles (LIPU-MB) may be safely used to open the blood-brain barrier to permit...
Does Prediagnosis Smoking Cessation Improve Overall Survival in Patients With NSCLC?
In a cohort study reported in JAMA Network Open, Wang et al found that overall survival in patients with non–small cell lung cancer (NSCLC) who stopped smoking prior to their cancer diagnosis was better than overall survival among those who were current smokers at the time of their diagnosis. Study ...
Cancer-Specific Mortality Rates Vary Widely Across the Globe, Study Finds
Investigators have found that in the majority of countries studied, the recent mortality rates for all major cancer types have decreased except for lung cancer among female patients and hepatic cancer among male patients—where increasing rates were observed in most countries, according to a novel...
Patients With Cervical Cancer May Be at Higher Risk for Urinary Tract Infections After Radical Hysterectomies
Patients with early-stage cervical cancer may have an increased risk of developing catheter-associated urinary tract infections following radical hysterectomies if they had a history of smoking or used catheters for more than 7 days postsurgery, according to a new study by Mercadel et al in the...
HPV Self-Collection Kits May Increase Cervical Cancer Screenings Among Underscreened, Underserved Patients
Researchers have found that mailing human papillomavirus (HPV) self-collection kits in addition to offering scheduling assistance to underscreened, underserved patients may increase the rate of cervical cancer screenings compared with scheduling assistance alone, according to a new study published...
Combined Delivery of DNX-2401 Plus Pembrolizumab May Be Safe and Effective in Patients With Recurrent Glioblastoma
Intratumoral delivery of the engineered oncolytic virus DNX-2401 in combination with subsequent immunotherapy with pembrolizumab may be safe and effective at improving survival outcomes in patients with recurrent glioblastoma, according to a study published by Nassiri et al in Nature Medicine....
Phase II Trial of Guadecitabine Plus Atezolizumab in Patients With Metastatic Bladder Cancer
Although hypomethylating agents previously appeared to be a promising treatment option for patients with bladder cancer refractory to immunotherapy, researchers were forced to halt a recent phase II clinical trial after patients experienced either no response to treatment or rapid tumor...
Immune Checkpoint Inhibitors Show Promise for People Living With HIV
New research involving people living with HIV treated with immune checkpoint inhibitors has provided valuable insights into the safety and efficacy of immunotherapy in this historically excluded population, according to data published by El Zarif et al in the Journal of Clinical Oncology. The...
Addition of Bevacizumab to Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer
As reported in The New England Journal of Medicine by Prager et al, the phase III SUNLIGHT trial has shown prolonged overall survival with the addition of bevacizumab to trifluridine/tipiracil (FTD-TPI) in previously treated patients with metastatic colorectal cancer. As stated by the...
Potential Utility of Polygenic Risk Scores in Cancer Screening in the United Kingdom
In a modeling study reported in The Lancet Oncology, Huntley et al found that the extension of UK cancer screening programs for breast, prostate, and colorectal cancers to a polygenic risk score (PRS)-defined high-risk group of patients with cancer may improve cancer case detection and avoidance of ...
Patients With Cancer May Prefer Telemedicine Appointments Over In-Person Visits When Both Are Available
Investigators have found that telemedicine may consistently outperform in-person visits for cancer care when assessed for access to care, provider response, and patient experience, according to a new study published by Patel et al in JNCCN–Journal of the National Comprehensive Cancer Network....
Immigrant Adults With Hepatocellular Carcinoma May Have Higher Survival Rates Than Those Born in the United States
Immigrant adult patients who have hepatocellular carcinoma and reside in the United States may have higher rates of survival compared with those who have the disease and were born in the United States, according to a new study published by Zhou et al in the Journal of the National Cancer Institute. ...
